A0,A0.35_Verb,A1,A2,Polarity,RelatedSentence
( Reuters ) -,reject.01,final offer from Pfizer,,Affirmative,"LONDON , May 19 ( Reuters ) - Britain 's AstraZeneca on Monday rejected a sweetened and final offer from Pfizer , puncturing the U.S. drugmaker 's plan for a merger to create the world 's biggest pharmaceuticals group . "
Pfizer 's,say.01,it had raised,,Affirmative,"The rebuff came nine hours after Pfizer said on Sunday night it had raised its takeover offer to 55 pounds a share , or around 70 billion pounds ( $ 118 billion ) in total , and would walk away if AstraZeneca did not accept it . "
Pfizer 's,raise.01,its takeover offer,,Affirmative,"The rebuff came nine hours after Pfizer said on Sunday night it had raised its takeover offer to 55 pounds a share , or around 70 billion pounds ( $ 118 billion ) in total , and would walk away if AstraZeneca did not accept it . "
"Britain 's AstraZeneca on Monday rejected a sweetened and `` final '' offer from Pfizer , puncturing the U.S. drugmaker 's plan for a merger to create the world 's biggest pharmaceuticals group",accept.01,Pfizer 's,,Affirmative,"The rebuff came nine hours after Pfizer said on Sunday night it had raised its takeover offer to 55 pounds a share , or around 70 billion pounds ( $ 118 billion ) in total , and would walk away if AstraZeneca did not accept it . "
The rejection,leave.02,some major shareholders,fuming as shares in AstraZeneca,Affirmative,The rejection left some major shareholders fuming as shares in AstraZeneca slumped 11 percent to close at 42.88 pounds after falling as much as 15 percent - their biggest ever intra-day decline . 
The rejection,fume.01,as shares in AstraZeneca,,Affirmative,The rejection left some major shareholders fuming as shares in AstraZeneca slumped 11 percent to close at 42.88 pounds after falling as much as 15 percent - their biggest ever intra-day decline . 
Chairman Leif Johansson,tell.01,he now saw,Reuters,Affirmative,"AstraZeneca Chairman Leif Johansson told Reuters he now saw no prospect of a deal with Pfizer before a deadline of May 26 set under British takeover rules , or any likelihood of that deadline being extended . "
AstraZeneca Chairman Leif Johansson,see.01,no prospect of,,Affirmative,"AstraZeneca Chairman Leif Johansson told Reuters he now saw no prospect of a deal with Pfizer before a deadline of May 26 set under British takeover rules , or any likelihood of that deadline being extended . "
Experts,say.01,Pfizer had left itself,,Affirmative,Experts also said Pfizer had left itself no room to return with a last - minute higher offer due to the strict takeover code . 
Pfizer 's,leave.01,no room,,Affirmative,Experts also said Pfizer had left itself no room to return with a last - minute higher offer due to the strict takeover code . 
Pfizer 's,want.01,to create,,Affirmative,"Pfizer wants to create the world 's largest drugs firm , with a headquarters in New York but a tax base in Britain , where corporate tax rates are lower than in the United States . "
Pfizer 's,create.01,largest drugs firm,,Affirmative,"Pfizer wants to create the world 's largest drugs firm , with a headquarters in New York but a tax base in Britain , where corporate tax rates are lower than in the United States . "
the U.S. drugmaker 's plan,meet.01,entrenched opposition from AstraZeneca,,Affirmative,"The plan has met entrenched opposition from AstraZeneca , as well as politicians and scientists who fear cuts to jobs and research . "
scientists,fear.01,cuts,,Affirmative,"The plan has met entrenched opposition from AstraZeneca , as well as politicians and scientists who fear cuts to jobs and research . "
AstraZeneca Chairman Leif Johansson,say.01,he had made clear in discussions with Pfizer,,Affirmative,"Johansson said he had made clear in discussions with Pfizer that his board could only recommend a bid that was more than 10 percent above an offer of 53.50 pounds made by Pfizer on Friday , which would amount to at least 58.85 pounds . "
AstraZeneca Chairman Leif Johansson,make.02,clear,,Affirmative,"Johansson said he had made clear in discussions with Pfizer that his board could only recommend a bid that was more than 10 percent above an offer of 53.50 pounds made by Pfizer on Friday , which would amount to at least 58.85 pounds . "
his board,recommend.01,a bid,,Affirmative,"Johansson said he had made clear in discussions with Pfizer that his board could only recommend a bid that was more than 10 percent above an offer of 53.50 pounds made by Pfizer on Friday , which would amount to at least 58.85 pounds . "
by Pfizer,make.LV,53.50 pounds made by Pfizer,,Affirmative,"Johansson said he had made clear in discussions with Pfizer that his board could only recommend a bid that was more than 10 percent above an offer of 53.50 pounds made by Pfizer on Friday , which would amount to at least 58.85 pounds . "
AstraZeneca Chairman Leif Johansson,blame.01,Pfizer,for calling,Affirmative,He blamed Pfizer for calling a halt to discussions after a telephone call lasting more than an hour with Pfizer 's chairman and CEO Ian Read on Sunday afternoon . 
AstraZeneca Chairman Leif Johansson,call.03,a halt,to discussions after,Affirmative,He blamed Pfizer for calling a halt to discussions after a telephone call lasting more than an hour with Pfizer 's chairman and CEO Ian Read on Sunday afternoon . 
AstraZeneca Chairman Leif Johansson,slam.02,said was,,Affirmative,"In addition to the inadequate price , Johansson also slammed what he said was a lack of industrial logic behind Pfizer 's move ; the risks posed to shareholders by the controversial tax plans ; and the threat to life science jobs in Britain , Sweden and the United States . "
by,pose.02,the risks posed to shareholders,to shareholders,Affirmative,"In addition to the inadequate price , Johansson also slammed what he said was a lack of industrial logic behind Pfizer 's move ; the risks posed to shareholders by the controversial tax plans ; and the threat to life science jobs in Britain , Sweden and the United States . "
by,drive.02,approach throughout,,Affirmative,"Pfizer 's approach throughout its pursuit of AstraZeneca appears to have been fundamentally driven by the corporate financial benefits to its shareholders of cost savings and tax minimisation , Johansson said in a statement . "
AstraZeneca Chairman Leif Johansson,say.01,appears,,Affirmative,"Pfizer 's approach throughout its pursuit of AstraZeneca appears to have been fundamentally driven by the corporate financial benefits to its shareholders of cost savings and tax minimisation , Johansson said in a statement . "
Pfizer 's,make.02,case,,Affirmative,"From our first meeting in January to our latest discussion yesterday , and in the numerous phone calls in between , Pfizer has failed to make a compelling strategic , business or value case . "
many of Johansson 's shareholders,think.01,management have done,,Affirmative,"We do not think the Astra management have done a good job on behalf of shareholders , said one fund manager at a top - 10 investor in the group . "
the Astra management,do.02,a good job on behalf of shareholders,,Affirmative,"We do not think the Astra management have done a good job on behalf of shareholders , said one fund manager at a top - 10 investor in the group . "
one fund manager at,say.01,We do not think,,Affirmative,"We do not think the Astra management have done a good job on behalf of shareholders , said one fund manager at a top - 10 investor in the group . "
Alastair Gunn of,say.01,has rejected,,Affirmative,Alastair Gunn of top - 30 shareholder Jupiter Fund Management said : We are disappointed the board of AstraZeneca has rejected Pfizer 's latest offer so categorically . 
the AstraZeneca board,reject.01,latest offer,,Affirmative,Alastair Gunn of top - 30 shareholder Jupiter Fund Management said : We are disappointed the board of AstraZeneca has rejected Pfizer 's latest offer so categorically . 
by,oppose.01,"proposed takeover ,",,Affirmative,"However , Pfizer 's proposed takeover , which would be the largest - ever foreign acquisition of a British company , is opposed by many scientists and politicians who fear it would undermine Britain 's science base . "
many scientists and politicians,fear.01,it would undermine,,Affirmative,"However , Pfizer 's proposed takeover , which would be the largest - ever foreign acquisition of a British company , is opposed by many scientists and politicians who fear it would undermine Britain 's science base . "
Pfizer 's proposed takeover,undermine.01,science base,,Affirmative,"However , Pfizer 's proposed takeover , which would be the largest - ever foreign acquisition of a British company , is opposed by many scientists and politicians who fear it would undermine Britain 's science base . "
The U.S. group,say.01,offer was final and,,Affirmative,The U.S. group said its new offer was final and could not be increased . 
The U.S. group,say.01,it would not make,,Affirmative,It said it would not make a hostile offer directly to AstraZeneca shareholders and would only proceed with an offer with the recommendation of the AstraZeneca board . 
The U.S. group,proceed.01,with,,Affirmative,It said it would not make a hostile offer directly to AstraZeneca shareholders and would only proceed with an offer with the recommendation of the AstraZeneca board . 
Pfizer 's,increase.01,the cash element in,,Affirmative,"Pfizer had also increased the cash element in its offer to 45 percent , under which AstraZeneca shareholders would get 1.747 shares in the enlarged company for each of their AstraZeneca shares and 24.76 pounds in cash . "
some major shareholders fuming as shares in AstraZeneca slumped 11 percent to close at 42.88 pounds after falling as much as 15 percent - their biggest ever intra-day decline,get.01,1.747 shares,,Affirmative,"Pfizer had also increased the cash element in its offer to 45 percent , under which AstraZeneca shareholders would get 1.747 shares in the enlarged company for each of their AstraZeneca shares and 24.76 pounds in cash . "
its new offer,represent.01,percent premium over,,Affirmative,The new offer represents a 15 - percent premium over the current value of a cash - and - share approach made on May 2 - worth 50 pounds a share at the time - which was also swiftly rejected by AstraZeneca . 
Read,say.01,he believed,,Affirmative,"Pfizer 's Read said he believed his proposal was compelling for AstraZeneca shareholders and expressed frustration at its refusal to talk , urging the British company 's shareholders to pressure its board to engage . "
Pfizer 's Read,believe.01,proposal was compelling for,,Affirmative,"Pfizer 's Read said he believed his proposal was compelling for AstraZeneca shareholders and expressed frustration at its refusal to talk , urging the British company 's shareholders to pressure its board to engage . "
his proposal,express.01,frustration at,,Affirmative,"Pfizer 's Read said he believed his proposal was compelling for AstraZeneca shareholders and expressed frustration at its refusal to talk , urging the British company 's shareholders to pressure its board to engage . "
shareholders,pressure.01,its board,to engage,Affirmative,"Pfizer 's Read said he believed his proposal was compelling for AstraZeneca shareholders and expressed frustration at its refusal to talk , urging the British company 's shareholders to pressure its board to engage . "
"Britain 's AstraZeneca on Monday rejected a sweetened and `` final '' offer from Pfizer , puncturing the U.S. drugmaker 's plan for a merger to create the world 's biggest pharmaceuticals group",have.03,six months,,Affirmative,"AstraZeneca will have six months to demonstrate that it was right to reject Pfizer 's offer , or face the prospect of a fresh approach , said analyst Mick Cooper at Edison Investment Research . "
analyst Mick Cooper at,say.01,AstraZeneca will have,,Affirmative,"AstraZeneca will have six months to demonstrate that it was right to reject Pfizer 's offer , or face the prospect of a fresh approach , said analyst Mick Cooper at Edison Investment Research . "
"Britain 's AstraZeneca on Monday rejected a sweetened and `` final '' offer from Pfizer , puncturing the U.S. drugmaker 's plan for a merger to create the world 's biggest pharmaceuticals group",initiate.01,talks,,Affirmative,"While Pfizer would have to wait on the sidelines until November , it would be possible for AstraZeneca to initiate talks from late August , if it decided it wants coax a higher offer . "
Pfizer 's,decide.01,it wants coax,,Affirmative,"While Pfizer would have to wait on the sidelines until November , it would be possible for AstraZeneca to initiate talks from late August , if it decided it wants coax a higher offer . "
Pfizer 's,want.01,coax,,Affirmative,"While Pfizer would have to wait on the sidelines until November , it would be possible for AstraZeneca to initiate talks from late August , if it decided it wants coax a higher offer . "
Pfizer 's,coax.01,a higher offer,,Affirmative,"While Pfizer would have to wait on the sidelines until November , it would be possible for AstraZeneca to initiate talks from late August , if it decided it wants coax a higher offer . "
Pfizer 's,say.01,it would consider,,Affirmative,Pfizer said last week it would consider a higher offer as it urged AstraZeneca 's board to enter talks . 
Pfizer 's,consider.01,a higher offer,,Affirmative,Pfizer said last week it would consider a higher offer as it urged AstraZeneca 's board to enter talks . 
Pfizer 's,urge.01,board,to enter talks,Affirmative,Pfizer said last week it would consider a higher offer as it urged AstraZeneca 's board to enter talks . 
board,enter.01,talks,,Affirmative,Pfizer said last week it would consider a higher offer as it urged AstraZeneca 's board to enter talks . 
The British firm,lay.01,details of,,Affirmative,The British firm has laid out details of its pipeline of new drugs and argues it has no need for a deal . 
The British firm,argue.01,it has,,Affirmative,The British firm has laid out details of its pipeline of new drugs and argues it has no need for a deal . 
The British firm,have.03,no need for,,Affirmative,The British firm has laid out details of its pipeline of new drugs and argues it has no need for a deal . 
many analysts,believe.01,are over-optimistic,,Affirmative,"However , many analysts believe its projections that it can increase sales by 75 percent to $ 45 billion a year by 2023 are over-optimistic . "
The British firm,increase.01,sales,,Affirmative,"However , many analysts believe its projections that it can increase sales by 75 percent to $ 45 billion a year by 2023 are over-optimistic . "
"Britain 's AstraZeneca on Monday rejected a sweetened and `` final '' offer from Pfizer , puncturing the U.S. drugmaker 's plan for a merger to create the world 's biggest pharmaceuticals group",have.03,half its roots,,Affirmative,"There has been a mounting political backlash against the proposed deal in Britain , the United States and Sweden , where AstraZeneca has half its roots . "
The Swedish government,launch.01,a concerted effort,,Affirmative,"The Swedish government launched a concerted effort on Friday against a merger that it fears will lead to cuts in science jobs and research , echoing concerns aired by British lawmakers at two parliamentary hearings last week , and fears for U.S. jobs in states where AstraZeneca has a large presence . "
The Swedish government,fear.01,will lead to cuts in,,Affirmative,"The Swedish government launched a concerted effort on Friday against a merger that it fears will lead to cuts in science jobs and research , echoing concerns aired by British lawmakers at two parliamentary hearings last week , and fears for U.S. jobs in states where AstraZeneca has a large presence . "
by,air.01,echoing concerns aired by,,Affirmative,"The Swedish government launched a concerted effort on Friday against a merger that it fears will lead to cuts in science jobs and research , echoing concerns aired by British lawmakers at two parliamentary hearings last week , and fears for U.S. jobs in states where AstraZeneca has a large presence . "
"Britain 's AstraZeneca on Monday rejected a sweetened and `` final '' offer from Pfizer , puncturing the U.S. drugmaker 's plan for a merger to create the world 's biggest pharmaceuticals group",have.03,a large presence,,Affirmative,"The Swedish government launched a concerted effort on Friday against a merger that it fears will lead to cuts in science jobs and research , echoing concerns aired by British lawmakers at two parliamentary hearings last week , and fears for U.S. jobs in states where AstraZeneca has a large presence . "
Minister David Cameron,say.01,he wanted,,Affirmative,"British Prime Minister David Cameron has said he wanted more assurances from Pfizer , in the event of a takeover , although as the head of the free - market Conservative Party he does not want to be seen to be deterring foreign corporate investment . "
British Prime Minister David Cameron,want.01,more assurances from Pfizer,,Affirmative,"British Prime Minister David Cameron has said he wanted more assurances from Pfizer , in the event of a takeover , although as the head of the free - market Conservative Party he does not want to be seen to be deterring foreign corporate investment . "
British Prime Minister David Cameron,want.01,to be seen,,Affirmative,"British Prime Minister David Cameron has said he wanted more assurances from Pfizer , in the event of a takeover , although as the head of the free - market Conservative Party he does not want to be seen to be deterring foreign corporate investment . "
British Prime Minister David Cameron,deter.01,foreign corporate investment,,Affirmative,"British Prime Minister David Cameron has said he wanted more assurances from Pfizer , in the event of a takeover , although as the head of the free - market Conservative Party he does not want to be seen to be deterring foreign corporate investment . "
Pfizer 's,give.01,year commitment to,,Affirmative,"Pfizer gave a five - year commitment to complete AstraZeneca 's new research centre in Cambridge , retain a factory in northern England and put a fifth of its research staff in Britain , but added that these pledges could be adjusted if circumstances changed significantly . "
Pfizer 's,add.01,pledges could be adjusted,,Affirmative,"Pfizer gave a five - year commitment to complete AstraZeneca 's new research centre in Cambridge , retain a factory in northern England and put a fifth of its research staff in Britain , but added that these pledges could be adjusted if circumstances changed significantly . "
The tax aspects of,spark.01,anger,,Affirmative,"The tax aspects of the deal , meanwhile , have sparked anger in the United States , where lawmakers are now considering legislation to prevent what are known as corporate inversions , under which U.S. companies re-incorporate overseas to avoid U.S. taxes . "
British lawmakers at two parliamentary hearings,consider.02,legislation,,Affirmative,"The tax aspects of the deal , meanwhile , have sparked anger in the United States , where lawmakers are now considering legislation to prevent what are known as corporate inversions , under which U.S. companies re-incorporate overseas to avoid U.S. taxes . "
British lawmakers at two parliamentary hearings,prevent.01,what are known as,,Affirmative,"The tax aspects of the deal , meanwhile , have sparked anger in the United States , where lawmakers are now considering legislation to prevent what are known as corporate inversions , under which U.S. companies re-incorporate overseas to avoid U.S. taxes . "
U.S. companies,avoid.01,U.S. taxes,,Affirmative,"The tax aspects of the deal , meanwhile , have sparked anger in the United States , where lawmakers are now considering legislation to prevent what are known as corporate inversions , under which U.S. companies re-incorporate overseas to avoid U.S. taxes . "
significantly,welcome.01,comments on,,Affirmative,We welcome comments on our articles for a limited period after their publication . 
